We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test Detects Rheumatoid Arthritis in At-Risk Individuals Before Symptoms

By LabMedica International staff writers
Posted on 06 Oct 2025

Rheumatoid arthritis (RA) is a debilitating autoimmune disorder that causes chronic joint inflammation, pain, and disability. More...

For decades, doctors have diagnosed the disease only after symptoms appear, by which time irreversible damage has often occurred. Millions of people endure years of misdiagnosis and progressive pain before treatment begins. Now, clinical tests could detect new early-warning signs (biomarkers and immune signatures) to identify who among at-risk individuals is most likely to develop RA.

In a seven-year study, researchers at the Allen Institute (Seattle, WA, USA) and the University of Colorado Anschutz (Aurora, CO, USA), along with collaborators, analyzed individuals carrying anticitrullinated protein antibodies (ACPAs) known biomarkers for RA risk — the team mapped how the immune system changes long before joint symptoms appear. The study provides the most detailed timeline yet of how RA develops from invisible immune dysfunction to full-blown disease.

The researchers tracked hundreds of at-risk participants over several years, studying the behavior of immune cells and gene activity across multiple tissues. They found widespread inflammation throughout the body, even before localized joint swelling began. Immune cells, such as B cells and T helper cells, shifted toward a pro-inflammatory state, while “naive” T cells exhibited early epigenetic reprogramming. The study also detected monocytes in the bloodstream resembling macrophages from inflamed joints, suggesting that the body was already preparing for joint-specific attacks.

These findings, published in Science Translational Medicine, provide powerful early-warning indicators that could allow clinicians to identify who among at-risk individuals is most likely to develop RA. Detecting these immune signatures in advance could enable doctors to monitor high-risk patients more closely and intervene before tissue damage occurs. By catching the disease at its earliest, invisible stage, the research points toward a major shift from reactive treatment to proactive prevention of autoimmune diseases.

The study’s insights into immune cell behavior could also help refine existing therapies or guide the development of new biologics targeting inflammation earlier in the disease process. Future research will aim to translate these biomarkers into clinical tests capable of predicting disease onset and identifying patients who would benefit most from early intervention.

“Overall, we hope this study raises awareness that rheumatoid arthritis begins much earlier than previously thought and that it enables researchers to make data-driven decisions on strategies to disrupt disease development,” said Mark Gillespie, Ph.D., co-senior author of the study.

Related Links:
Allen Institute
University of Colorado Anschutz


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Portable Electronic Pipette
Mini 96
New
Gold Member
Hybrid Pipette
SWITCH
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The TriVerity IVD test includes the TriVerity cartridge and the Myrna instrument (Photo courtesy of Inflammatix)

Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients

When a patient enters the emergency department in critical condition, clinicians must rapidly decide whether the patient has an infection, whether it is bacterial or viral, and whether immediate treatment... Read more

Technology

view channel
Image: The technology could be used for the early diagnosis of diseases such as cancers and Alzheimer\'s (Photo courtesy of PolyU)

3D Micro-Printed Sensors to Advance On-Chip Biosensing for Early Disease Detection

Early-stage disease diagnosis depends on the ability to detect biomarkers with exceptional sensitivity and precision. However, traditional biosensing technologies struggle with achieving this at the micro-scale,... Read more

Industry

view channel
Image: ELITechGroup’s unique Real-Time PCR technologies include the revolutionary Minor Groove Binder (Photo courtesy of ELITechGroup)

ELITech and Hitachi High-Tech to Develop Automated PCR Testing System for Infectious Diseases

Molecular testing has become central to diagnosing and monitoring infectious diseases by analyzing genetic information. The use of PCR during the COVID-19 pandemic showed its value, but traditional systems... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.